© The Institution of Engineering and Technology
Nanoparticulate drug delivery systems are of considerable therapeutic interest for delivery of drugs across from the blood–brain barrier. In this study, the ability of sodium chloride (NaCl) and different percentages of a water-soluble form of natural vitamin E, on the formation of poly(lactide-co-glycolide) (PLGA) nanoparticles (NPs), as a potential carrier for drug delivery, was investigated. According to the obtained results, by increasing the percentage of natural vitamin E, the average particle size decreased and the range of diameters came closer. After using 0.26 w/v % vitamin E, the average size of the PLGA particles became <100 nm. Moreover, the particles containing NaCl led to the formation of even smaller particles. In addition, no obvious cytotoxicity was observed at various natural vitamin E amounts in one and three days, and the modified PLGA NPs could be considered biocompatible since they showed a little decrease in cellular viability.
References
-
-
1)
-
20. Zhang, Z., Tan, S., Feng, S.Sh.: ‘Review vitamin E TPGS as a molecular biomaterial for drug delivery’, Biomaterials, 2012, 33, pp. 4889–4906 (doi: 10.1016/j.biomaterials.2012.03.046).
-
2)
-
28. Jain, K.K.: ‘Nanobiotechnology-based strategies for crossing the blood–brain barrier’, Nanomedicine, 2012, 7, (8), 1225–1233 (doi: 10.2217/nnm.12.86).
-
3)
-
13. Yan, A., Bussche, A.V.D., Kane, A.B., Hurt, R.H.: ‘Tocopheryl polyethylene glycol succinate as a safe, antioxidant surfactant for processing carbon nanotubes and fullerenes’, Carbon N Y., 2007, 45, (13), pp. 2463–2470 (doi: 10.1016/j.carbon.2007.08.035).
-
4)
-
12. Soppimath, K.S., Aminabhavi, T.M.: ‘Ethyl acetate as a dispersing solvent in the production of poly(DL-lactide-co-glycolide) microspheres: effect of process parameters and polymer type’, J. Microencapsulation, 2002, 19, pp. 281–292 (doi: 10.1080/02652040110105319).
-
5)
-
39. Savic, S., Weber, C., Tamburic, S., Savic, M., Müller-Goymann, C.: ‘Topical vehicles based on natural surfactant/fatty alcohols mixed emulsifier: the influence of two polyols on the colloidal structure and in vitro/in vivo skin performance’, J. Pharm Sci., 2009, 98, (6), pp. 2073–90 (doi: 10.1002/jps.21591).
-
6)
-
37. Russel, J., Reiter, R.J.: ‘Oxidative damage in the central nervous system: protection by melatonin’, Prog. Neurobiol., 1998, 56, pp. 359–384 (doi: 10.1016/S0301-0082(98)00052-5).
-
7)
-
19. Gonnet, M., Lethuaut, L., Boury, F.: ‘New trends in encapsulation of liposoluble vitamins’, J. Control. Release, 2010, 146, (3), pp. 276–290 (doi: 10.1016/j.jconrel.2010.01.037).
-
8)
-
10. DeMerlis, C.C., Schoneker, D.R.: ‘Review of the oral toxicity of polyvinyl alcohol (PVA)’, Food Chem. Toxicol., 2003, 41, pp. 319–326 (doi: 10.1016/S0278-6915(02)00258-2).
-
9)
-
33. Tosi, G., Badiali, L., Ruozi, B.: ‘Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?’, Nanomedicine (Lond), 2012, 7, pp. 365–382 (doi: 10.2217/nnm.11.98).
-
10)
-
29. Jain, K.K.: ‘Nanobiotechnology-based drug delivery to the central nervous system’, Neurodegener. Dis., 2007, 4, (4), pp. 287–291 (doi: 10.1159/000101884).
-
11)
-
16. Yang, Y., McClements, D.J.: ‘Encapsulation of vitamin E in edible emulsions fabricated using a natural surfactant’, Food Hydrocolloids, 2013, 30, pp. 712–720 (doi: 10.1016/j.foodhyd.2012.09.003).
-
12)
-
38. Do, J.H., An, J., Joun, Y.S., Chung, D.J., Kim, J.H.: ‘Cellular-uptake behavior of polymer nanoparticles into consideration of biosafety’, Macromol. Res., 2008, 16, (8), pp. 695–703 (doi: 10.1007/BF03218583).
-
13)
-
15. McClements, D.J.: ‘Emulsion design to improve the delivery of functional lipophilic components’, Annu. Rev. Food Sci Technol., 2010, 1, (1), pp. 241–269 (doi: 10.1146/annurev.food.080708.100722).
-
14)
-
9. Nair, B.: ‘Final report on the safety assessment of polyvinyl alcohol’, Int. J. Toxicol., 1998, 17, pp. 67–92 (doi: 10.1177/109158189801700505).
-
15)
-
11. Panyam, J., Labhasetwar, V.: ‘Dynamics of endocytosis and exocytosis of poly(D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells’, Pharm. Res., 2003, 20, pp. 212–220 (doi: 10.1023/A:1022219003551).
-
16)
-
22. Mu, L., Feng, S.S.: ‘PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio’, Pharm. Res., 2003, 20, pp. 1864–72 (doi: 10.1023/B:PHAM.0000003387.15428.42).
-
17)
-
32. Feng, S.S., Zeng, W., Teng Lim, Y., et al: ‘Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment’, Nanomedicine (Lond), 2007, 2, (3), pp. 333–44 (doi: 10.2217/17435889.2.3.333).
-
18)
-
35. Dalwadi, G., Sunderland, V.B.: ‘Purification of PEGylated nanoparticles using tangential flow filtration (TFF)’, Drug Dev. Ind. Pharm., 2007, 33, pp. 1030–1039 (doi: 10.1080/03639040601180143).
-
19)
-
7. Kulkarni, P.V., Roney, C.A., Antich, P.P., Bonte, F.J., Raghu, A.V., Aminabhavi, T.M.: ‘Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimers disease’, Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol., 2010, 2, (1), pp. 35–47.
-
20)
-
34. Thorne, R.G., Nicholson, C.: ‘In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space’, Proc. Natl. Acad. Sci. USA, 2006, 103, (14), pp. 5567–5572 (doi: 10.1073/pnas.0509425103).
-
21)
-
23. Mu, L., Feng, S.S.: ‘A novel controlled release formulation for the anticancer drug paclitaxel (Taxol (R)): PLGA nanoparticles containing vitamin E TPGS’, J. Control Release, 2003, 86, pp. 33–48 (doi: 10.1016/S0168-3659(02)00320-6).
-
22)
-
31. Lee, S.C., Oh, J.T., Jang, M.H., Chung, S.: ‘Quantitative analysis of polyvinyl alcohol on the surface of poly (D,L-lactide-coglycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration’, J. Control. Release, 1999, 59, (2), pp. 123–132 (doi: 10.1016/S0168-3659(98)00185-0).
-
23)
-
21. Mu, L., Feng, S.S.: ‘Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol (R))’, J. Control Release, 2002, 80, pp. 129–44 (doi: 10.1016/S0168-3659(02)00025-1).
-
24)
-
30. Barbu, E., Molnàr, E., Tsibouklis, J.: ‘The potential for nanoparticle-based drug delivery to the brain: overcoming the blood–brain barrier’, Expert Opin. Drug Deliv., 2009, 6, (6), pp. 553–565 (doi: 10.1517/17425240902939143).
-
25)
-
5. Jalali, N., Moztarzadeh, F., Mozafari, M., Asgari, Sh., Motevalian, M., Naghavi Alhosseini, S.: Surface modification of poly(lactide-co-glycolide) nanoparticles by d-α-tocopheryl polyethylene glycol 1000 succinate as potential carrier for the delivery of drugs to the brain, Colloids Surf. A, Physicochem. Eng. Aspects, 2011, 392, pp. 335–342 (doi: 10.1016/j.colsurfa.2011.10.012).
-
26)
-
4. Amjadi, I., Rabiee, M., Hosseini, M.S., Mozafari, M.: Synthesis and characterization of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles as a sustained-release anticancer drug delivery system, Appl. Biochem. Biotechnol., 2012, 168, (6), pp. 1434–1447 (doi: 10.1007/s12010-012-9868-4).
-
27)
-
25. Mah, E., Noh, S.K., Ballard, K.D., Park, H.J., Volek, J.S., Bruno, R.S.: ‘Supplementation of a γ-toocopherol-rich mixture of tocopherols in healthy men protects against vascular endothelial dysfunction induced by postprandial hyperglycemia’, J. Nutritional Biochem., 2013, 24, (1), pp. 196–203 (doi: 10.1016/j.jnutbio.2012.04.015).
-
28)
-
3. Roney, C., Kulkarni, P., Arora, V., et al: Targeted Nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease, J Control Release, 2005, 108, (2–3), pp. 193–21 (doi: 10.1016/j.jconrel.2005.07.024).
-
29)
-
2. Pardridge, W.M.: Blood–brain barrier delivery, Drug. Discov. Today., 2007, 129, (1–2), pp. 54–61 (doi: 10.1016/j.drudis.2006.10.013).
-
30)
-
6. Mundargi, R.C., Babu, V.R., Rangaswamy, V., Patel, P., Aminabhavi, T.M.: Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives, J. Control. Release, 2008, 125, pp. 193–209 (doi: 10.1016/j.jconrel.2007.09.013).
-
31)
-
24. Eastman Chemical Company: ‘Vitamin E TPGS NF, properties and applications’, Publication EFC-226A., Kingsport, TN, 1998.
-
32)
-
14. Kesisoglou, F., Panmai, S., Wu, Y.H.: ‘Application of nanoparticles in oral delivery of immediate release formulations’, Current Nanosci., 2007, 3, (2), pp. 183–190 (doi: 10.2174/157341307780619251).
-
33)
-
1. Abbott, J.: Physiology of the blood–brain barrier and its consequences for drug transport to the brain, Int. Congr. Ser., 2005, 277, pp. 3–18 (doi: 10.1016/j.ics.2005.02.008).
-
34)
-
17. Evans, H.M., Bishop, K.S.: ‘On the existence of a hitherto unrecognized dietary factor essential for reproduction’, Science, 1922, 56, (1458), pp. 650–651 (doi: 10.1126/science.56.1458.650).
-
35)
-
36. Amjadi, I., Rabiee, M., Hosseini, M.S., Sefidkon, F., Mozafari, M.: ‘Nanoencapsulation of Hypericum perforatum and doxorubicin anticancer agents in PLGA nanoparticles through double emulsion technique’, Micro Nano Lett., 2013, 8, (5), pp. 243–247 (doi: 10.1049/mnl.2012.0920).
-
36)
-
8. Jalali, N., Moztarzadeh, F., Mozafari, M., Asgari, S., Shokri, S., Alhosseini, S.N.: ‘Chitosan-surface modified poly(lactide-co-glycolide) nanoparticles as an effective drug delivery system’. 18th Iranian Conf. of Biomedical Engineering, , pp. 109–114.
-
37)
-
26. Beamish, R.E.: ‘Vitamin E – then and now’, Can. J. Cardiol., 1993, 9, pp. 29–31.
-
38)
-
18. Zingg, J.M.: ‘Vitamin E: an overview of major research directions’, Mol. Aspects Med., 2007, 28, pp. 400–422 (doi: 10.1016/j.mam.2007.05.004).
http://iet.metastore.ingenta.com/content/journals/10.1049/iet-nbt.2013.0053
Related content
content/journals/10.1049/iet-nbt.2013.0053
pub_keyword,iet_inspecKeyword,pub_concept
6
6